Specifically, clinical studies have demonstrated that nonsense variants in STK11, which predict loss of STK11 function, correlate with primary resistance to PD-1 axis inhibitors in KRAS-mutant lung adenocarcinoma patients (10,11). This evidence concerns the gene STK11 and lung adenocarcinoma.